Calithera Biosciences (STU:2CB0) LT-Debt-to-Total-Asset : 0.01 (As of Dec. 2022)

View and export this data going back to 2014. Start your Free Trial

What is Calithera Biosciences LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Calithera Biosciences's long-term debt to total assests ratio for the quarter that ended in Dec. 2022 was 0.01.

Calithera Biosciences's long-term debt to total assets ratio declined from Dec. 2021 (0.03) to Dec. 2022 (0.01). It may suggest that Calithera Biosciences is progressively becoming less dependent on debt to grow their business.

Calithera Biosciences LT-Debt-to-Total-Asset Historical Data

The historical data trend for Calithera Biosciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calithera Biosciences LT-Debt-to-Total-Asset Chart

Calithera Biosciences Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.04

0.03

0.01

Calithera Biosciences Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.03	0.03	0.02	0.01	0.01

Calithera Biosciences LT-Debt-to-Total-Asset Calculation

Calithera Biosciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (A: Dec. 2022 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2022 )	/	Total Assets (A: Dec. 2022 )
	=	0.128	/	27.07
	=

Calithera Biosciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (Q: Dec. 2022 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2022 )	/	Total Assets (Q: Dec. 2022 )
	=	0.128	/	27.07
	=

Calithera Biosciences (STU:2CB0) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Calithera Biosciences LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Calithera Biosciences's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Calithera Biosciences (STU:2CB0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calithera Biosciences Inc (STU:2CB0) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

343 Oyster Point Boulevard, Suite 200, South San Francisco, CA, USA, 94080

Website

https://www.calithera.com

Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the United States. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications.

Calithera Biosciences (STU:2CB0) Headlines

No Headlines